Quotables
"It is my heart-warmed and world-embracing Christmas hope and aspiration that all of us, the high, the low, the rich, the poor, the admired, the despised, the loved, the hated, the civilized, the savage (every man and brother of us all throughout the whole earth), may eventually be gathered together in a heaven of everlasting rest and peace and bliss, except the inventor of the telephone. "
Mark Twain ; Christmas greetings, 1890
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 8080658 | Material for organic electroluminescent element and organic electroluminescent element employing the same A material for organic electroluminescence devices for use as a host material in combination with at least one phosphorescent metal complex contains a compound represented by formula 1: wherein R | 12/20/2011 |
| 7732599 | Process for preparing tetrahydrobiopterin and analogs of tetrahydrobiopterin Process for the preparation of tetrahydrobiopterin from neopterin and/or 6-substituted pterins with an improved yield and a high stereoselectivity. Also disclosed herein are novel individual intermediates prepared in the preparation of tetrahydrobiopterin, such as s... | 06/08/2010 |
| 7601833 | Process for preparing substituted 5-amino-pyrazolo-[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines A process for preparing substituted 5-amino-pyrazolo[4,3-e]-1,2,4-triazolo-[1,5-c]pyrimidine compounds having an aminoalkyl substituent at the 7-position is disclosed, wherein the pyrimidine ring is cyclized using a cyanating agent. ... | 10/13/2009 |
| 7576202 | Tritium-traced saxitoxin dihydrochloride and method for the production thereof The invention relates to a tritium-traced saxitoxin dihydrichloride of formula (I) whose radioactivity ranges from 15-31 Ci/mmol and to a novel method for introducing tritium into a molecule comprising stages required for introducing tritium label by isotope exchang... | 08/18/2009 |
| 7511138 | Farnesyl transferase inhibiting tricyclic quinazoline derivatives substituted with carbon-linked imidazoles or triazoles This invention comprises the novel compounds of formula (I) wherein r, s, t, R1, R2, R3, R4, R5, and R6 have defined meanings, having farnesyl transferase inhibiting activity; their preparation, compo... | 03/31/2009 |
| 7507822 | Process for preparing substituted 5-amino-pyrazolo-[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines A process for preparing substituted 5-amino-pyrazolo[4,3-e]-1,2,4-triazolo-[1,5-c]pyrimidine compounds having an aminoalkyl substituent at the 7-position is disclosed. ... | 03/24/2009 |
| 7435740 | Adenosine Areceptor modulators A class of novel antagonists for the adenosine A3 receptor are disclosed. These compounds are useful as therapeutic agents for a number of diseases and medical conditions that are mediated by the A3 receptor. The compounds of this invention are... | 10/14/2008 |
| 7414058 | Adenosine Areceptor antagonists for the treatment of extra-pyramidal syndrome and other movement disorders There is disclosed a method for the treatment of Extra Pyramidal syndrome (EPS) comprising the administration of an adenosine A2a receptor antagonist, alone or in combination with other agents useful for treating EPS. ... | 08/19/2008 |
| 7407964 | Caspase inhibitors and uses thereof This invention provides novel caspase inhibitors of formula I: wherein R1 is hydrogen, CHN2, R, or —CH2Y; R is an aliphatic group, an aryl group, an aralkyl group, a heterocyclyl group, or... | 08/05/2008 |
| 7388014 | Quinazoline derivatives and therapeutic use thereof Quinazoline derivatives represented by the general formula pharmacologically acceptable salts thereof, and compositions containing such compounds are described. Methods for using the compounds for treatment of hyperprolifer... | 06/17/2008 |
| 7371757 | Fused heterocycles as inhibitors of glutamate racemase(MURI) This invention relates to novel compounds having formula: (I) or (II) and to their pharmaceutical compositions and to their methods of use. These novel compounds provide a treatment or prophylaxis of H. pylori infection. ... | 05/13/2008 |
| 7368449 | 2-alkynyl- and 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine Areceptor antagonists Compounds having the structural formula I or a pharmaceutically acceptable salt thereof, wherein R is | 05/06/2008 |
| 7332491 | Dihydropteridione derivatives, process for their manufacture and their use as medicament Disclosed are new dihydropteridinones of general formula (I) whereby the groups L, R1, R2, R3, R4 and R5 have the meanings given in the claims and specificat... | 02/19/2008 |
| 7329668 | Pyrazolopurine-based tricyclic compounds and pharmaceutical compositions comprising same The present invention provides for pyrazolopurine-based tricyclic compounds having the formula (I), wherein R1, R2, R3, R4, R5 and R6 are as descr... | 02/12/2008 |
| 7329667 | CRF receptor antagonists The present invention relates to tricyclic pyrimidines compounds of formula (I) including stereoisomers, prodrugs and pharmaceutically acceptable salts or solvates thereof, to processes for their preparation, to ... | 02/12/2008 |
| 7329748 | Method for the production of riboflavin of modification b/c in granular form The present invention relates to an improved process for preparing riboflavin of the B/C modification in granule form. Furthermore, the invention relates to the riboflavin preparation process wherein riboflavin of the A modification is (a) dissolved in aqueous miner... | 02/12/2008 |
| 7319103 | Non-imidazole tertiary amines as histamine 3 receptor inhibitors for the treatment of cognitive and sleep disorders, obesity and other CNS disorders This invention relates to compounds having pharmacological activity, to compositions containing these compounds, and to a method of treatment employing the compounds and compositions. More particularly, this invention concerns certain non-imidazole tertiary amine de... | 01/15/2008 |
| 7288543 | Opioid receptor antagonists A compound of the formula (I) (I) wherein the variables X1 to X6, Ra, Rb, R1 to R7 including R3′, E, p, j, y, z, A, B and C are as described or a pharmaceutically acceptable salt, solvate, enantiomer, racemate, diastereomer or mixtures thereof, useful for the trea... | 10/30/2007 |
| 7285561 | Imidazo-substituted compounds as p38 kinase inhibitors The present invention discloses compounds corresponding to formula I: wherein A, Z, Z1, Y, R1 and R2 are as defined in the specification, as well as pharmaceutical formulations, m... | 10/23/2007 |
| 7285559 | Imidazo-substituted compounds as p38 kinase inhibitors The present invention discloses compounds corresponding to formula I: wherein A, Z, Z1, Y, R1 and R2 are as defined in the specification, as well as pharmaceutical formulations, m... | 10/23/2007 |
| 7282575 | Functional peptide nucleic acid monomer and process for producing the same A compound represented by the general formula (I) below: In the formula, A is as defined in the specification and B denotes where n is an integer of 1 to 4, ... | 10/16/2007 |
| 7273871 | Phenyl-5,6,6A,7,8,9-hexahydro-4H-1,4,9-triaza-phenalene derivatives as CRF antagonists The present invention relates to tricyclic pyridines compounds of formula (I) including stereoisomers, prodrugs and pharmaceutically acceptable salts or solvates thereof: ... | 09/25/2007 |
| 7271171 | Adenosine Areceptor modulators The compounds of the following formula: wherein R, R2, R3 and A have the meanings given in the specification, are endowed with selective A3 adenosine receptor antagonist activity.... | 09/18/2007 |
| 7235659 | Process for preparing substituted 5-amino-pyrazolo-[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines A process for preparing substituted 5-amino-pyrazolo[4,3-e]-1,2,4-triazolo-[1,5-c]pyrimidine compounds having an aminoalkyl substituent at the 7-position is disclosed. ... | 06/26/2007 |
| 7223861 | Process for preparing substituted 5-amino-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidines A process for preparing substituted 5-amino-pyrazolo[4,3-e]-1,2,4-triazolo-[1,5-c]pyrimidine compounds having an aminoalkyl substituent at the 7-position is disclosed, wherein the pyrimidine ring is cyclized using a cyanating agent. ... | 05/29/2007 |
| 7220747 | Method for preventing damage to or rejuvenating a cellular blood component using mitochondrial enhancer This invention provides methods for treating cellular blood components and other cells containing mitochondria to improve vital qualities of the cells by contacting the cells with a mitochondrial enhancer to the cells. Mitochondrial enhancers prevent damage to and r... | 05/22/2007 |
| 7157451 | Heterocyclic dihydropyrimidine compounds Novel heterocyclic dihydropyrimidine compounds useful as inhibitors of potassium channel function (especially inhibitors of the Kv1 subfamily of voltage gated K+ channels, especially inhibitors Kv1.5 which has been linked to the ultr... | 01/02/2007 |
| 7144887 | Substituted 1,2,3-triazolo[1,5-a]quinazolines for enhancing cognition The present invention provides a compound of formula (I) in which R1 is generally hydrogen or CF3, R2 is generally hydrogen, W is a cyclic amine, a heterocycle or a group L-Y—X where L-Y is a linking portion and X is generally an a... | 12/05/2006 |
| 7132536 | Triaza- and tetraaza-anthracenedione derivatives, their preparation and their use as pharmaceuticals The present invention relates to triaza- and tetraaza-anthracenedione derivatives of the formula I, wherein A, B and R1 to R5 are as defined herein. The compounds of formula I are valuable p... | 11/07/2006 |
| 7112674 | Organic electroluminescent device based on 2,5-diaminoterephthalic acid derivatives The invention relates to an organic electroluminescent device which contains 2,5-diaminoterephthalic acid derivatives of formula 1a as emitter substances in one or several emitter layers in a pure or doped manner. The ring A is a triple unsaturated benzene ring wher... | 09/26/2006 |
| 7081462 | Imidazo-substituted compounds as p38 kinase inhibitors The present invention discloses compounds corresponding to formula I: wherein A, Z, Z1, Y, R1 and R2 are as defined in the specification, as well as pharmaceutical formulations, m... | 07/25/2006 |
| 7074797 | Pyrazolopyrimidines as CRF receptor antagonists This invention concerns compounds of formula including the stereoisomers and the pharmaceutically acceptable acid addition salt forms thereof, wherein R1 is NR4R5 or OR5 | 07/11/2006 |
| 7071333 | Triazolopurine-based tricyclic compounds and pharmaceutical compositions comprising same The present invention provides for triazolopurine-based tricyclic compounds having the formula (I), wherein R1, R2, R3, R4, and R5 are as described herein. T... | 07/04/2006 |
| 7067655 | Adenosine A2a receptor antagonists Compounds having the structural formula I or a pharmaceutically acceptable salt thereof, wherein R is optionally substituted phenyl, cycloalkenyl, or heteroaryl; X is alkylene or —C(O)CH2 | 06/27/2006 |
| 7064204 | Pharmaceutically active compounds having a tricyclic pyrazolotriazolopyrimidine ring structure and methods of use New compounds having a tricyclic pyrazolotriazolopyrimidine ring structure are provided and methods of using those compounds for a variety of therapeutic indications. ... | 06/20/2006 |
| 7060824 | Pyrrolotriazolopyrimidinone derivatives This invention relates to new therapeutically useful 8-(disubstituted)phenyl-6,9-dihydro-5H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-c]pyrimidine-5-one and 8-phenyl-6,9-dihydro-5H-pyrrolo[3,2-e][1,2,4]triazolo[4,3-c]pyrimidine-5-one derivatives of formula (I): wherein: —... | 06/13/2006 |
| 7034016 | 8-phenyl-6,9-dihydro-[1,2,4]triazolo[3,4-i]purin-5-one derivatives 8-phenyl-6,9-dihydro-[1,2,4]triazolo[3,4-i]purin-5-one derivatives of formula (I): or a pharmaceutically acceptable salt thereof processes for their preparation, pharmaceutical compositions containing them and their use... | 04/25/2006 |
| 7022686 | A1 adenosine receptro antagonists Compounds of Formula I and II are disclosed as antagonists of subtype A1 adenosine receptors. These compounds are useful for treatment of various diseases and disorders, including systemic hypertension, renal failure, diabetes, asthma, an edematous condition, conges... | 04/04/2006 |
| 7018997 | Tricyclic 6-alkylidene-penems as β-lactamase inhibitors The present invention provides a compound of formula I, pharmaceutical compositions and the use thereof for the treatment of bacterial infection or disease in a patient in need thereof. wherein one of A and B denotes hy... | 03/28/2006 |
| 7005430 | Fused purine derivatives A condensed purine derivative represented by Formula (I): wherein X—Y-Z represents R1N—C═O or N═C—W, R2 represents a hydrogen atom, a substituted or unsubstituted lower alkyl group, a sub... | 02/28/2006 |
